Rahul Aggarwal

MD

Developmental therapeutics specialist
Genitourinary oncologist
Cancer researcher and sports enthusiast

Dr. Rahul Aggarwal is a specialist in cancers of the genital and urinary organs. He cares for patients at the UCSF Helen Diller Family Comprehensive Cancer Center. He also serves as director of the UCSF STAND (Supportive Therapy in Androgen Deprivation) Clinic, which provides comprehensive care to men who are receiving androgen deprivation therapy, hormone therapy for prostate cancer.

As a member of the Developmental Therapeutics Genitourinary Cancer Program, Aggarwal enrolls patients with advanced solid tumor malignancies into early-phase clinical trials of novel targeted treatments. His research focuses on developing hormonal treatment strategies that reduce the toxicity of androgen deprivation therapy for men with advanced prostate cancer. He is also interested in developing new molecular imaging techniques that will help predict how advanced solid tumors will respond to treatment.

Aggarwal earned his medical degree from the Northwestern University Feinberg School of Medicine. At UCSF, he completed an internship and residency in internal medicine, followed by a clinical fellowship in hematology and oncology.

Aggarwal has also been a research fellow in developmental therapeutics at Genentech. He is a member of the American Society of Clinical Oncology (ASCO) and recipient of the ASCO/Conquer Cancer Foundation Young Investigator Award.

  • Education

    Northwestern University Feinberg School of Medicine, 2006

  • Residencies

    UCSF Medical Center, Internal Medicine, 2009

  • Fellowships

    UCSF Medical Center, Hematology/Oncology, 2013

  • Board Certifications

    Medical Oncology, American Board of Internal Medicine

    Hematology, American Board of Internal Medicine

  • Academic Title

    Professor

It's an honor to help take care of people with cancer, and I strive each and every day to improve outcomes for our patients.

Conditions I specialize in

Where I see patients (4)

    My reviews

    4.9

    Overall Experience
    317 Ratings
    About our process
    Nov 29, 2024
    Caring, professional, respectful, knowledgeable, outstanding care.
    Nov 26, 2024
    Always a pleasure to speak with Dr. Aggerwal.
    Aug 27, 2024
    Excellent meeting.
    Aug 14, 2024
    he is an excellent doctor
    Jun 21, 2024
    I listen to and follow the instructions and treatment recommendations provided by Dr. Aggarwal and I'm very satisfied with the status and outcomes of the treatment prescribed to date.
    Jun 15, 2024
    I am fortunate to be his care
    May 16, 2024
    I consider myself to be extremely fortunate to have Dr Aggarwal and his extraordinary team at my side!
    May 15, 2024
    Rahul is the best!
    May 15, 2024
    I have sent many people/friends to UCSF for treatment. All are doing very well. It's a World Class facility.
    May 03, 2024
    Dr Aggarwal is the finest physician I have ever had in my life.
    Mar 28, 2024
    Great
    Mar 21, 2024
    Outstanding experience in every aspect
    Mar 15, 2024
    Dr continues to demonstrate the highest level of knowledge, compassion and communication skills.
    Mar 07, 2024
    Dr. Aggarwal is wonderful
    Dec 01, 2023
    The doctor that I deal with Was very very helpful and I hope to continue working with you guys
    Nov 27, 2023
    Very professional
    Nov 08, 2023
    I have a good friend ready to get treated by UCSF Urology Group right now - he is receiving World Class care and advice.
    Oct 24, 2023
    Super
    Oct 19, 2023
    The Doctor was wonderful. Easy to follow and answered all of our question.
    Oct 13, 2023
    I have the best team of doctors
    Sep 28, 2023
    I appreciate the respect and care Dr. Aggarwall extends to us
    Sep 27, 2023
    UCSF is the best, thank you
    Sep 25, 2023
    The doctor was such a wonderful listener.
    Sep 22, 2023
    Fantastic resource
    Sep 20, 2023
    We always feel like we are getting special care with Dr Aggarwal
    Sep 13, 2023
    My admiration for the doctor Aggarwal and his team
    Aug 30, 2023
    I love my care
    Aug 23, 2023
    Great experience
    Aug 23, 2023
    Dr. Aggarwal is terrific!!!
    Aug 18, 2023
    Always good
    Aug 01, 2023
    Dr. Aggarwal has been providing me with informed, up to date care options for over 10 years. He always listens to my concerns and suggestions with respect. I would likely not still be alive without his coordination of my treatment.
    Jul 28, 2023
    Excellent
    Jul 22, 2023
    Dr Aggarwal exceeds every expectation that I have in a provider. His knowledge, attentiveness and demeanor is first rate. He certainly lives up to the highest standard of practitioners that I have encountered at UCSF. I continue to feel blessed to have UCSF an integral part of my medical oncological team.
    Jul 20, 2023
    Always a pleasure speaking to Dr. Aggarwal. Very informative as well as direct and to the point.
    Jul 18, 2023
    Always great experiences
    Jul 16, 2023
    utstanding provider. The best I've ever had.
    Jul 15, 2023
    Dr. Aggarwal is the absolute best doctor. He is an excellent communicator and listener. He addresses all questions in a clear and concise manner. He shows his concern for us. Our best doctor ever.
    Jun 22, 2023
    Dr. Agarwal is the best.!!
    Jun 13, 2023
    Dr. Aggarwal is a caring, knowledgeable and skillful physician. He is empathic and considerate. We're very grateful for his care! Perhaps it would be useful to have a little more time to discus or hear his understanding of the development of patient's conditions and overall outlook on his progress.
    May 31, 2023
    Excellent care-
    May 19, 2023
    Dr Aggarwal is the best!
    May 18, 2023
    Dr. Aggarwal is excellent in his knowledge, professional, and communication skills. I feel quite fortunate to be able to work with him.
    May 16, 2023
    Great
    May 04, 2023
    I have built a strong trusted relationship with Dr Aggarwal over many years and treatments. He fully understands my goals, has delivered outstanding (world class) care, and remembers my unique situation each time we meet.
    Apr 26, 2023
    The care is second to none. His entire staff is amazing!
    Apr 21, 2023
    I really like Dr Aggarawal, he has always been very attentive, knowelegable and caring
    Mar 25, 2023
    DR AGARWAHL IS THE BEST.
    Mar 23, 2023
    Comments meant for Dr Aggarwal
    Mar 22, 2023
    Excellent quality of care
    Mar 21, 2023
    I'm lucky to have Dr. Aggarwal as my oncologist. He's easy to talk to, open to questions, encourages discussion about treatment and how I'm doing.
    Mar 15, 2023
    Dr. Aggarwal is kind and compassionate.
    Mar 01, 2023
    Excellent
    Mar 01, 2023
    Great Doc!!!!!

    Selected research

    See all research
    Decorative Caduceus

    Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer

    rPFS is defined as the amount of time from the initiation of study therapy and the day of first documented radiographic disease progression per RECIST version 1.1 and PCWG3 criteria. The proportion of patients without radiographic...

    Recruiting

    Decorative Caduceus

    Phase 1 Trial of RP-3467 Alone and in Combination with Olaparib in Participants with Advanced S...

    Incidence and severity of treatment-emergent adverse events (TEAEs) as assessed per NCI CTCAE v5.0 criteria

    Recruiting

    Decorative Caduceus

    Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

    Recruiting

    Decorative Caduceus

    A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastati...

    To compare the PFS between treatment arms. PFS is defined as the time (month) interval between date of randomization and date of radiographic disease progression or death for those without prior evidence of progression, as assesse...

    Recruiting

    Decorative Caduceus

    Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With So...

    On overall response will be reported as a percentage of participants with a complete response (CR) or partial response (PR) as measured by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

    Recruiting

    Decorative Caduceus

    Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

    To assess the safety and tolerability of MOMA-313 given as a single-agent or in combination with olaparib

    Recruiting

    Decorative Caduceus

    Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Pr...

    DLTs reported during ModA Part 1.

    Recruiting

    Decorative Caduceus

    A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the...

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment...

    Recruiting

    Decorative Caduceus

    ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant ...

    Defined as either objective response per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria (complete response (CR), partial response (PR)) or confirmed >= 50% decline from serum prostate-specific antigen (PSA) at ...

    Recruiting

    Decorative Caduceus

    FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostat...

    A minimum of 3 patients will be treated at each dose level. If < 33%of patients (i.e. 0 of 3 patients, or 1 of 6 patients) within a cohort have a dose-limiting toxicity (DLT in Cycle 1, then enrollment of the next cohort may comme...

    Recruiting

    Contact me

    Share